In silico and in vitro analysis of a new potential antifungal substance, 2-Bromo-Nphenylacetamide, against invasive candidiasis isolates
-
Published:2022-02-04
Issue:3
Volume:50
Page:
-
ISSN:1909-6356
-
Container-title:Revista Colombiana de Ciencias Químico-Farmacéuticas
-
language:
-
Short-container-title:Rev. Colomb. Cienc. Quím. Farm.
Author:
De Moura Sousa Romulo Pereira,De Figuerêdo Silva Daniele,Cavalcante Oliveira Neuza Maria,Vieira Da Silva Pontes Zélia Braz,Diniz Neto Hermes,Vilar Cordeiro Laísa,Ramalho de Figueiredo Pedro Thiago,Farias de Oliveira Rafael,da Silva Souza Helivaldo Diógenes,De Athayde Filho Petrônio Filgueiras,De Oliveira Lima Edeltrudes
Abstract
Introduction: invasive candidiasis is related to high rates of morbidity and mortality. There are few classes of drugs available for the treatment of this type of infection and the index of resistant strains is increasing. Such circumstances highlight that the search for new pharmacotherapeutic alternatives is increasingly necessary. This study investigated 2-Bromo-N-phenylacetamide, a substance whose antifungal activity has not yet been reported. Objective: to evaluate its activity against invasive candidiasis isolates, by determining the minimum inhibitory and fungicide concentrations. Meth-odology: molecular docking was performed to investigate the possible mechanism of action of the substance. The substance was also associated with fluconazole, to assess the viability of the combination in clinical practice. The minimum inhibitory concen-trations ranged between 4 to 32 μg/mL, and it acts in a fungicidal way. Results: molec-ular docking suggests that 2-Bromo-N-phenylacetamide possibly acts on the fungal plasma membrane. And the association of 2-Bromo-N-phenylacetamide with flucon-azole against resistant strains showed an indifferent effect. Conclusion: further studies should be carried out to elucidate the potential of this substance, which may become a future drug candidate to treat invasive candidiasis and other fungal infections.
Publisher
Universidad Nacional de Colombia
Subject
Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics
Reference18 articles.
1. A.M. Doi, A.C.C. Pignatari, M.B. Edmond, A.R. Marra, L.F.A. Camargo, R.A. Siqueira, V.P. Mota, A.L. Colombo, Epidemiolog y and microbiologic characte-rization of nosocomial candidemia from a Brazilian national surveillance pro-gram,PloS One, 11(1), e0146909 (2016). 2. M.F. Gonzalez-Lara, L. Ostrosky-Zeichner, Invasive candidiasis, Seminars in Respiratory and Critical Care Medicine3. 4. , 41(01), 3-12 (2020). 3. M.C. Arendrup, T.F. Patterson, Multidrug-resistant Candida: epidemio-log y, molecular mechanisms, and treatment,The Journal of Infectious Diseases, 216(Suppl. 3), S445-S451 (2017). 4. A. Moraes-Nicola, P. Albuquerque, H. Costa-Paes, L. Fernandes, F.F. Costa, E. Seli-Kioshima, A.K. Rodrigues-Abadio, A. Lorenzetti-Bocca, M. Sueli-Felipe, Antifungal drugs: new insights in research & development, Pharmacolog y & Therapeutics,195, 21-38 (2019). 5. C.P. Kaushik, R. Luxm, M. Kumar, D. Singh, K. Krishan, A. Pahwa, One-pot facile synthesis, crystal structure and antifungal activity of 1,2,3-triazoles bridged with amine-amide functionalities, Synthetic Communications, 49(1), 118-128 (2019).
|
|